Rche sur le Syst e Nerveux Central (GRSNC) (M.B., L.
Rche sur le Syst e Nerveux Central (GRSNC) (M.B., L.L., D.V., H.G.); and Centre interdisciplinaire de recherche sur le cerveau et l’apprentissage (CIRCA) (D.V., H.G.), Universitde Montr l, Montr l, Qu ec, Canada; and Centre de Recherche de l’Institut de G iatrie de Montr l, Montr l, Qu ec, Canada (H.G.).13.14.15.Sources of FundingThis study was supported by the Heart and Stroke Foundation of Canada (HSFC), Fonds de Recherche du Qu ec-Sant(FRQS), the Canada Foundation for Innovation (CFI), and the Canadian Institutes of Health Research (CIHR). H e Girouard was also the holder of a new investigator award from the FRQS plus the HSFC.16.DisclosuresNone.17.Supplementary MaterialFigures S1S18.
Circulation Reports Circ Rep 2021; three: 504 510 doi: 10.1253/circrep.CR-21-ORIGINAL ARTICLECardiovascular InterventionTORII S et al.Antiplatelet Effect of Single Antiplatelet Therapy With Prasugrel and Oral Anticoagulation Just after Stent Implantation within a Rabbit Arteriovenous Shunt ModelSho Torii, MD, PhD; Tadashi Yamamoto, MD, PhD; Norihito Nakamura, MD; Takeshi Ijichi, MD, PhD; Ayako Yoshikawa; Yusuke Ito, PhD; Atsuhiro Sugidachi, PhD; Yuji Ikari, MD; Gaku Nakazawa, MD, PhDBackground: Antiplatelet therapy following stent implantation in patients requiring oral anticoagulation (OAC) is controversial because triple therapy (i.e., dual antiplatelet therapy [DAPT] with OAC) is associated using a high risk of bleeding. Approaches and Final results: In this study, 21 rabbits have been divided into 5 groups: prasugrel and warfarin (Prasugrel+OAC group); aspirin and warfarin (Aspirin+OAC group); prasugrel, aspirin, and warfarin group (Triple group); prasugrel and aspirin (Conventional DAPT group); and no medication (mGluR1 Activator Source Control group). The treated groups were administered medication for 1 week. An arteriovenous shunt loop was established from the rabbit carotid artery to the jugular vein and 2 bare metal stents have been deployed within a silicone tube. Right after 1 h of circulation, the volume of thrombi was evaluated quantitatively by measuring the level of protein. Bleeding time was measured in the exact same time. The volume with the thrombus (quantity of protein) about stent struts was lowest in the Triple group, followed by the Prasugrel+OAC and Standard DAPT groups, and was highest in the Control group. Bleeding time was the longest inside the Triple group, followed by the Aspirin+OAC, Prasugrel+OAC, Standard DAPT, and Control groups. Conclusions: This study suggests that prasugrel with OAC can be a feasible antithrombotic regimen following stent implantation in individuals who demand OAC therapy. Crucial Words: Atrial fibrillation; Dual antiplatelet therapy; Oral anticoagulant therapy; Percutaneous coronary intervention; Stent thrombosisual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 receptor inhibitor has come to be the gold regular following percutaneous coronary intervention (PCI) to stop stent SIRT1 Modulator Formulation thrombosis (ST).1 With all the quantity of patients with atrial fibrillation (AF) rising, it was lately reported that about 10 of individuals who underwent PCI had AF.two Triple therapy, consisting of DAPT plus oral anticoagulants (OAC), had been recommended to stop both ST and cardiogenic embolism. Nonetheless, recent randomized manage studies (RCTs) comparing triple therapy and dual therapy with an OAC and P2Y12 receptor inhibitor have demonstrated a significant reduction in bleeding events as well as similar threat of ST.3 Therefore, the latest Japanese guideline recommends triple therapy throughout.
